EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Long-term outcomes of autologous cell therapy in patients with ischaemic diabetic foot ulcers and no-option chronic limb threatening ischaemia

Langzeitoutcomes einer autologen Zelltherapie bei Patient:innen mit ischämischen diabetischen Fußulzera und chronischer Extremitäten-bedrohender Ischämie ohne Therapieoption

Meloni Marco, Bellizzi Ermanno, Uccioli Luigi, Morosetti Daniele, Giurato Laura, Bonanni Federico Rolando, Ruotolo Valeria, Andreadi Aikaterini, Bellia Alfonso, Lauro Davide

Acta Diabetologica · 22.06.2026 · 63 (8) · 1447-1457

DOI: 10.1007/s00592-026-02721-5 ↗

Auf einen Blick

Bei 78 Patient:innen war PB-MNC-Therapie plus Standardversorgung nach 24 Monaten mit mehr Heilungen und weniger Majoramputationen und Mortalität verbunden als alleinige Standardversorgung.

Fragestellung

Welches Langzeitoutcome hat eine PB-MNC-Therapie bei Patient:innen mit ischämischen DFU und NO-CLTI im Vergleich zur Standardversorgung?

Methode

Prospektive, single-centre, beobachtende kontrollierte Studie; Einschluss von Januar 2017 bis September 2023; 24 Monate Follow-up.

Ergebnisse

78 Patient:innen: 48 mit PB-MNCs plus SoC, 30 mit konventioneller Therapie. Heilung 60,4 vs. 20 %, Majoramputation 12,5 vs. 26,7 %, Mortalität 27,1 vs. 46,7 %; Wiederaufnahme wegen rezidivierender CLTI 3/48 (6,2 %).

Schlussfolgerung der Autor:innen

Bei Patient:innen mit ischämischen DFU und NO-CLTI war eine adjuvante PB-MNC-Therapie mit besseren Langzeitoutcomes im Vergleich zur konventionellen Therapie assoziiert.

Kernaussagen

  • Heilung nach 24 Monaten: 60,4 vs. 20 %
  • Majoramputation und Mortalität waren in der PB-MNC-Gruppe niedriger
  • Rezidivierende CLTI mit Wiederaufnahme trat bei 3/48 (6,2 %) auf

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Acta Diabetologica, online erschienen am 22.06.2026. Verfasst von Meloni Marco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy. meloni.marco@libero.it. Hauptthemen laut MEDLINE: Diabetic Foot, Ischemia, Chronic Limb-Threatening Ischemia, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma Tor Vergata.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Patients with ischaemic diabetic foot ulcers (DFUs) and no-option chronic limb-threatening ischaemia (CLTI) are reported to have a high risk of major amputation and mortality. Peripheral blood mononuclear cell (PB-MNCs) therapy has emerged as a promising adjunctive strategy, but long-term data remain limited. The study aimed to evaluate the long-term outcomes of PB-MNC therapy in patients with DFUs and NO-CLTI.

Methods

This prospective, single-centre, observational, controlled study included patients with ischaemic DFUs and no-option CLTI enrolled between January 2017 and September 2023. No-option CLTI was defined by a technical failure of lower limb revascularization with the absence of any below-the-ankle vessel and/or indirect revascularization with TcPO₂ values < 30 mmHg in the wound angiosome area. Patients were divided into two groups: those receiving PB-MNCs therapy plus standard of care (SoC) and those treated only with SOC based on conventional guidelines. PB-MNCs were administered by intramuscular injections along the anatomical area of the wound-related artery (2 or 3 cycles, 21–42 days apart). At 24 months of follow-up, outcomes assessed were healing, major amputation, and mortality. In the PB-MNC group, hospital readmission for recurrent CLTI requiring repeat revascularization was also recorded.

Results

Overall, 78 patients were included: 48 in the PB-MNCs group and 30 in the conventional therapy group. The mean age was 73.7 years, 84.6% were male, and most had type 2 diabetes (92.3%). At the baseline assessment, 71.8% of DFUs were infected, 83.3% were > 5 cm², and 88.5% had gangrene. At 24 months, the PB-MNCs group showed a higher rate of healing (60.4 vs. 20%, p < 0.0001), lower rate of major amputation (12.5 vs. 26.7%, p = 0.0004), and mortality (27.1 vs. 46.7%, p = 0.0002) than the control group. CLTI recurrence requiring readmission occurred in 3/48 (6.2%) among patients in the PB-MNC group.

Conclusions

In patients with ischaemic DFUs and NO-CLTI, adjunctive PB-MNCs therapy was associated with better long-term outcomes in comparison to conventional therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic FootIschemiaChronic Limb-Threatening IschemiaCell- and Tissue-Based TherapyLeukocytes, MononuclearHumansMaleFemaleAgedProspective StudiesTreatment OutcomeMiddle AgedTransplantation, AutologousAmputation, SurgicalWound Healing

Stichwörter der Autor:innen

DiabetesDiabetic footPeripheral arterial diseasePeripheral blood mononuclear cellsRevascularization

Autor:innen und Institutionen

  • Department of Systems Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy. meloni.marco@libero.it.
  • Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, 00133, Italy. meloni.marco@libero.it.
  • UOC Diabetic Foot, IRCCS MULTIMEDICA, Sesto San Giovanni, Milan, Italy.
  • Division of Endocrinology and Diabetes, CTO Andrea Alesini Hospital, Rome, 00145, Italy.
  • Interventional Radiology Unit, Dipartimento Processi Assistenziali Integrati, University of Rome Tor Vergata, Rome, Italy.
  • Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, 00133, Italy.

Förderung

  • Università degli Studi di Roma Tor Vergata

Zitieren

APA

Marco, M., Ermanno, B., Luigi, U., Daniele, M., Laura, G., Rolando, B. F., Valeria, R., Aikaterini, A., Alfonso, B., & Davide, L. (2026). Long-term outcomes of autologous cell therapy in patients with ischaemic diabetic foot ulcers and no-option chronic limb threatening ischaemia. Acta Diabetologica, 63(8), 1447-1457. https://doi.org/10.1007/s00592-026-02721-5

Vancouver

Marco M, Ermanno B, Luigi U, Daniele M, Laura G, Rolando BF, et al. Long-term outcomes of autologous cell therapy in patients with ischaemic diabetic foot ulcers and no-option chronic limb threatening ischaemia. Acta Diabetologica. 2026;63(8):1447-1457. doi:10.1007/s00592-026-02721-5

BibTeX
@article{Marco2026,
  author = {Marco, Meloni and Ermanno, Bellizzi and Luigi, Uccioli and Daniele, Morosetti and Laura, Giurato and Rolando, Bonanni Federico and Valeria, Ruotolo and Aikaterini, Andreadi and Alfonso, Bellia and Davide, Lauro},
  title = {Long-term outcomes of autologous cell therapy in patients with ischaemic diabetic foot ulcers and no-option chronic limb threatening ischaemia},
  journal = {Acta Diabetologica},
  year = {2026},
  volume = {63},
  number = {8},
  pages = {1447--1457},
  doi = {10.1007/s00592-026-02721-5}
}
Kostenlos starten →